- home
- Advanced Search
- COVID-19
- 2021-2021
- European Commission
- HAL Descartes
- COVID-19
- 2021-2021
- European Commission
- HAL Descartes
Loading
description Publicationkeyboard_double_arrow_right Article 2021 Belgium, FrancePublisher:Springer Science and Business Media LLC Funded by:EC | MOOD, EC | RECoVEREC| MOOD ,EC| RECoVERDelphine Planas; Nell Saunders; Piet Maes; Florence Guivel-Benhassine; Cyril Planchais; Julian Buchrieser; William-Henry Bolland; Françoise Porrot; Isabelle Staropoli; Frederic Lemoine; Hélène Péré; David Veyer; Julien Puech; Julien Rodary; Guy Baele; Simon Dellicour; Joren Raymenants; Sarah Gorissen; Caspar Geenen; Bert Vanmechelen; Tony Wawina-Bokalanga; Joan Martí-Carreras; Lize Cuypers; Aymeric Sève; Laurent Hocqueloux; Thierry Prazuck; Félix A. Rey; Etienne Simon-Loriere; Timothée Bruel; Hugo Mouquet; Emmanuel André; Olivier Schwartz;The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa1-3. It has since spread to many countries and is expected to rapidly become dominant worldwide. The lineage is characterized by the presence of around 32 mutations in spike-located mostly in the N-terminal domain and the receptor-binding domain-that may enhance viral fitness and enable antibody evasion. Here we isolated an infectious Omicron virus in Belgium from a traveller returning from Egypt. We examined its sensitivity to nine monoclonal antibodies that have been clinically approved or are in development4, and to antibodies present in 115 serum samples from COVID-19 vaccine recipients or individuals who have recovered from COVID-19. Omicron was completely or partially resistant to neutralization by all monoclonal antibodies tested. Sera from recipients of the Pfizer or AstraZeneca vaccine, sampled five months after complete vaccination, barely inhibited Omicron. Sera from COVID-19-convalescent patients collected 6 or 12 months after symptoms displayed low or no neutralizing activity against Omicron. Administration of a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titres 6-fold to 23-fold lower against Omicron compared with those against Delta. Thus, Omicron escapes most therapeutic monoclonal antibodies and, to a large extent, vaccine-elicited antibodies. However, Omicron is neutralized by antibodies generated by a booster vaccine dose. ispartof: NATURE vol:602 issue:7898 pages:671-+ ispartof: location:England status: published
add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/d41586-021-03827-2&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 1K citations 1,056 popularity Top 0.01% influence Top 0.1% impulse Top 0.01% Powered by BIP!more_vert add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/d41586-021-03827-2&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Preprint 2021 FrancePublisher:Cold Spring Harbor Laboratory Funded by:NIH | Mechanisms of viral prote..., ANR | NICOFIVE, EC | SCORE +2 projectsNIH| Mechanisms of viral proteases in coronavirus replication and pathogenesis ,ANR| NICOFIVE ,EC| SCORE ,ANR| microFLU-REASSORT ,NIH| Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2K.Y. Chen; T. Krischuns; L. Ortega Varga; E. Harigua-Souiai; S. Paisant; A. Zettor; J. Chiaravalli; A. Delpal; D. Courtney; A. O'Brien; S.C. Baker; E. Decroly; C. Isel; F. Agou; Y. Jacob; A. Blondel; N. Naffakh;pmc: PMC8722588 , PMC8906008
AbstractEffective drugs against SARS-CoV-2 are urgently needed to treat severe cases of infection and for prophylactic use. The main viral protease (nsp5 or 3CLpro) represents an attractive and possibly broad-spectrum target for drug development as it is essential to the virus life cycle and highly conserved among betacoronaviruses. Sensitive and efficient high-throughput screening methods are key for drug discovery. Here we report the development of a gain-of-signal, highly sensitive cell-based luciferase assay to monitor SARS-CoV-2 nsp5 activity and show that it is suitable for high-throughput screening of compounds in a 384-well format. A benefit of miniaturisation and automation is that screening can be performed in parallel on a wild-type and a catalytically inactive nsp5, which improves the selectivity of the assay. We performed molecular docking-based screening on a set of 14,468 compounds from an in-house chemical database, selected 359 candidate nsp5 inhibitors and tested them experimentally. We identified four molecules, including the broad-spectrum antiviral merimepodib/VX-497, which show anti-nsp5 activity and inhibit SARS-CoV-2 replication in A549-ACE2 cells with IC50 values in the 4-21 µM range. The here described assay will allow the screening of large-scale compound libraries for SARS-CoV-2 nsp5 inhibitors. Moreover, we provide evidence that this assay can be adapted to other coronaviruses and viruses which rely on a viral protease.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8722588Data sources: PubMed CentralHAL Descartes; HAL-Pasteur; Mémoires en Sciences de l'Information et de la Communication; HAL AMUArticle . 2022License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.18.473303&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen hybrid 9 citations 9 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8722588Data sources: PubMed CentralHAL Descartes; HAL-Pasteur; Mémoires en Sciences de l'Information et de la Communication; HAL AMUArticle . 2022License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.18.473303&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Preprint 2021 FrancePublisher:Cold Spring Harbor Laboratory Funded by:EC | STRUGGLE, EC | QuanTIIEC| STRUGGLE ,EC| QuanTIIAuthors: Ruiz Ortega, María; Spisak, Natanael; Mora, Thierry; Walczak, Aleksandra M.;Ruiz Ortega, María; Spisak, Natanael; Mora, Thierry; Walczak, Aleksandra M.;Adaptive immunity’s success relies on the extraordinary diversity of protein receptors on B and T cell membranes. Despite this diversity, the existence of public receptors shared by many individuals gives hope for developing population wide vaccines and therapeutics. Yet many of these public receptors are shared by chance. We present a statistical approach, defined in terms of a probabilistic V(D)J recombination model enhanced by a selection factor, that describes repertoire diversity and predicts with high accuracy the spectrum of repertoire overlap in healthy individuals. The model underestimates sharing between repertoires of individuals infected with SARS-CoV-2, suggesting strong antigen-driven convergent selection. We exploit this discrepancy to identify COVID-associated receptors, which we validate against datasets of receptors with known viral specificity. We study their properties in terms of sequence features and network organization, and use them to design an accurate diagnosis tool for predicting SARS-CoV-2 status from repertoire data.
PLoS Genetics arrow_drop_down https://doi.org/10.1101/2021.1...Other literature type . Preprint . 2021 . 2022Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2022add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.17.473105&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesgold 10 citations 10 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert PLoS Genetics arrow_drop_down https://doi.org/10.1101/2021.1...Other literature type . Preprint . 2021 . 2022Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2022add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.17.473105&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Preprint , Other literature type 2021Embargo end date: 15 Dec 2021 United Kingdom, FrancePublisher:Apollo - University of Cambridge Repository Funded by:EC | VEO, ANR | INCEPTION, EC | RECoVEREC| VEO ,ANR| INCEPTION ,EC| RECoVERTran Kiem, Cécile; Bosetti, Paolo; Paireau, Juliette; Crépey, Pascal; Salje, Henrik; Lefrancq, Noémie; Fontanet, Arnaud; Benamouzig, Daniel; Boëlle, Pierre-Yves; Desenclos, Jean-Claude; Opatowski, Lulla; Cauchemez, Simon;The shielding of older individuals has been proposed to limit COVID-19 hospitalizations while relaxing general social distancing in the absence of vaccines. Evaluating such approaches requires a deep understanding of transmission dynamics across ages. Here, we use detailed age-specific case and hospitalization data to model the rebound in the French epidemic in summer 2020, characterize age-specific transmission dynamics and critically evaluate different age-targeted intervention measures in the absence of vaccines. We find that while the rebound started in young adults, it reached individuals aged ���80 y.o. after 4 weeks, despite substantial contact reductions, indicating substantial transmission flows across ages. We derive the contribution of each age group to transmission. While shielding older individuals reduces mortality, it is insufficient to allow major relaxations of social distancing. When the epidemic remains manageable (R close to 1), targeting those most contributing to transmission is better than shielding at-risk individuals. Pandemic control requires an effort from all age groups. Funder: We acknowledge financial support from the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Sant�� Publique France, the INCEPTION project (PIA/ANR-16-COV-0005), the European Union���s Horizon 2020 research and innovation program under grant 101003589 (RECOVER) and 874735 (VEO), AXA and Groupama. Funder: AXA Research Fund (Le Fonds AXA pour la Recherche); doi: https://doi.org/10.13039/501100001961
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021 . Peer-reviewedFull-Text: http://europepmc.org/articles/PMC8617041Data sources: PubMed CentralHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461/documentHAL Descartes; HAL-Rennes 1; HAL-Pasteur; Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2021License: CC BY NC NDHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la Communication; Hal-DiderotPreprint . 2021License: CC BY NC NDHAL DescartesArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461v3/documentData sources: HAL Descartesadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.17863/cam.78875&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu4 citations 4 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021 . Peer-reviewedFull-Text: http://europepmc.org/articles/PMC8617041Data sources: PubMed CentralHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461/documentHAL Descartes; HAL-Rennes 1; HAL-Pasteur; Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2021License: CC BY NC NDHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la Communication; Hal-DiderotPreprint . 2021License: CC BY NC NDHAL DescartesArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461v3/documentData sources: HAL Descartesadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.17863/cam.78875&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Conference object , Preprint , Article 2021 FrancePublisher:IEEE Funded by:EC | Scale-FreeBackEC| Scale-FreeBackAuthors: Niazi, Muhammad Umar B.; Kibangou, Alain; Canudas-de-Wit, Carlos; Nikitin, Denis; +2 AuthorsNiazi, Muhammad Umar B.; Kibangou, Alain; Canudas-de-Wit, Carlos; Nikitin, Denis; Tumash, Liudmila; Bliman, Pierre-Alexandre;Testing is a crucial control mechanism for an epidemic outbreak because it enables the health authority to detect and isolate the infected cases, thereby limiting the disease transmission to susceptible people, when no effective treatment or vaccine is available. In this paper, an epidemic model that incorporates the testing rate as a control input is presented. The proposed model distinguishes between the undetected infected and the detected infected cases with the latter assumed to be isolated from the disease spreading process in the population. Two testing policies, effective during the onset of an epidemic when no treatment or vaccine is available, are devised: (i) best-effort strategy for testing (BEST) and (ii) constant optimal strategy for testing (COST). The BEST is a suppression policy that provides a lower bound on the testing rate to stop the growth of the epidemic. The COST is a mitigation policy that minimizes the peak of the epidemic by providing a constant, optimal allocation of tests in a certain time interval when the total stockpile of tests is limited. Both testing policies are evaluated by their impact on the number of active intensive care unit (ICU) cases and the cumulative number of deaths due to COVID-19 in France. arXiv admin note: substantial text overlap with arXiv:2010.15438
https://hal.archives... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/cdc45484.2021.9683300&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen 0 citations 0 popularity Average influence Average impulse Average Powered by BIP!more_vert https://hal.archives... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/cdc45484.2021.9683300&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 France, ItalyPublisher:Springer Science and Business Media LLC Funded by:ANR | EVALCOVID-19, EC | MOOD, EC | RECoVERANR| EVALCOVID-19 ,EC| MOOD ,EC| RECoVERLaura Di Domenico; Chiara E. Sabbatini; Pierre-Yves Boëlle; Chiara Poletto; Pascal Crépey; Juliette Paireau; Simon Cauchemez; François Beck; Harold Noel; Daniel Lévy-Bruhl; Vittoria Colizza;After one year of stop-and-go COVID-19 mitigation, in the spring of 2021 European countries still experienced sustained viral circulation due to the Alpha variant. As the prospect of entering a new pandemic phase through vaccination was drawing closer, a key challenge remained on how to balance the efficacy of long-lasting interventions and their impact on the quality of life.Focusing on the third wave in France during spring 2021, we simulate intervention scenarios of varying intensity and duration, with potential waning of adherence over time, based on past mobility data and modeling estimates. We identify optimal strategies by balancing efficacy of interventions with a data-driven "distress" index, integrating intensity and duration of social distancing.We show that moderate interventions would require a much longer time to achieve the same result as high intensity lockdowns, with the additional risk of deteriorating control as adherence wanes. Shorter strict lockdowns are largely more effective than longer moderate lockdowns, for similar intermediate distress and infringement on individual freedom.Our study shows that favoring milder interventions over more stringent short approaches on the basis of perceived acceptability could be detrimental in the long term, especially with waning adherence.In the spring of 2021, social distancing measures were strengthened in France to control the third wave of COVID-19 cases. While such measures are needed to slow the spread of the virus, they have a significant impact on the population’s quality of life. Here, we use mathematical modelling based on hospital admission data and behavioural and health data (including data on mobility, indicators of social distancing, risk perception, and mental health) to evaluate optimal COVID-19 control strategies. We look at the effects of interventions, their sustainability and the population’s adherence to them over time. We find that shorter, more stringent measures are likely to have similar effects on viral circulation and healthcare burden to long-lasting, less stringent but less sustainable interventions. Our findings have implications for the design and implementation of public health measures to control future COVID-19 waves.
Archivio istituziona... arrow_drop_down HAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03690599/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s43856-021-00057-5&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesgold 16 citations 16 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert Archivio istituziona... arrow_drop_down HAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03690599/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s43856-021-00057-5&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 France, France, NetherlandsPublisher:Elsevier BV Funded by:ANR | FIGHT-HF, EC | HOMAGEANR| FIGHT-HF ,EC| HOMAGEAuthors: Ferreira, João Pedro; Girerd, Nicolas; Rocca, Hans-Peter Brunner-La; Pellicori, Pierpaolo; +3 AuthorsFerreira, João Pedro; Girerd, Nicolas; Rocca, Hans-Peter Brunner-La; Pellicori, Pierpaolo; Cleland, John; Rossignol, Patrick; Zannad, Faiez;International audience
Archives of Cardiova... arrow_drop_down Archives of Cardiovascular DiseasesArticle . 2021Full-Text: http://europepmc.org/articles/PMC8576594Data sources: PubMed CentralArchives of Cardiovascular Diseases; NARCISArticle . 2021add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.acvd.2021.10.003&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 3 citations 3 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert Archives of Cardiova... arrow_drop_down Archives of Cardiovascular DiseasesArticle . 2021Full-Text: http://europepmc.org/articles/PMC8576594Data sources: PubMed CentralArchives of Cardiovascular Diseases; NARCISArticle . 2021add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.acvd.2021.10.003&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 FrancePublisher:Wiley Publicly fundedFunded by:IRC, ANR | PSL, EC | PhotoMedMetIRC ,ANR| PSL ,EC| PhotoMedMetGil‐Moles, Maria; Türck, Sebastian; Basu, Uttara; Pettenuzzo, Andrea; Bhattacharya, Saurav; Rajan, Ananthu; Ma, Xiang; Büssing, Rolf; Wölker, Jessica; Burmeister, Hilke; Hoffmeister, Henrik; Schneeberg, Pia; Prause, Andre; Lippmann, Petra; Kusi‐Nimarko, Josephine; Hassell‐Hart, Storm; McGown, Andrew; Guest, Daniel; Lin, Yan; Notaro, Anna; Vinck, Robin; Karges, Johannes; Cariou, Kevin; Peng, Kun; Qin, Xue; Wang, Xing; Skiba, Joanna; Szczupak, Łukasz; Kowalski, Konrad; Schatzschneider, Ulrich; Hemmert, Catherine; Gornitzka, Heinz; Milaeva, Elena R.; Nazarov, Alexey A.; Gasser, Gilles; Spencer, John; Ronconi, Luca; Kortz, Ulrich; Cinatl, Jindrich; Bojkova, Denisa; Ott, Ingo;Abstract The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are commonly underrepresented in compound libraries that are used for screening in drug discovery campaigns, however, there is growing evidence for their role in medicinal chemistry. Based on previous results, we have selected more than 100 structurally diverse metal complexes for profiling as inhibitors of two relevant SARS‐CoV‐2 replication mechanisms, namely the interaction of the spike (S) protein with the ACE2 receptor and the papain‐like protease PLpro. In addition to many well‐established types of mononuclear experimental metallodrugs, the pool of compounds tested was extended to approved metal‐based therapeutics such as silver sulfadiazine and thiomersal, as well as polyoxometalates (POMs). Among the mononuclear metal complexes, only a small number of active inhibitors of the S/ACE2 interaction was identified, with titanocene dichloride as the only strong inhibitor. However, among the gold and silver containing complexes many turned out to be very potent inhibitors of PLpro activity. Highly promising activity against both targets was noted for many POMs. Selected complexes were evaluated in antiviral SARS‐CoV‐2 assays confirming activity for gold complexes with N‐heterocyclic carbene (NHC) or dithiocarbamato ligands, a silver NHC complex, titanocene dichloride as well as a POM compound. These studies might provide starting points for the design of metal‐based SARS‐CoV‐2 antiviral agents. Despite their increasing relevance in medicinal chemistry, metal complexes are still underrepresented in compound screening libraries for drug discovery. In this work more than 100 metal complexes were evaluated as inhibitors of two targets in the SARS‐CoV‐2 life cycle, the interaction of the spike protein with the ACE2 receptor and the protease PLpro. The most active inhibitors were studied for antiviral effects in SARS‐CoV‐2 infected cells and led to the discovery of active compounds that will provide starting points for future drug design.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8653295Data sources: PubMed CentralMémoires en Sciences de l'Information et de la CommunicationArticle . 2021Full-Text: https://hal.science/hal-03722017/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1002/chem.202103258&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen hybrid 33 citations 33 popularity Top 10% influence Top 10% impulse Top 10% Powered by BIP!visibility 44visibility views 44 download downloads 10 Powered bymore_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8653295Data sources: PubMed CentralMémoires en Sciences de l'Information et de la CommunicationArticle . 2021Full-Text: https://hal.science/hal-03722017/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1002/chem.202103258&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Other literature type , Conference object 2021 United Kingdom, Belgium, United Kingdom, United Kingdom, France, United Kingdom, United Kingdom, United Kingdom, United Kingdom, Netherlands, FrancePublisher:American Medical Association (AMA) Publicly fundedFunded by:WT | Implementing an innovativ..., NHMRC | the role of host MHC in H..., EC | PREPARE +2 projectsWT| Implementing an innovative electronic registry in a new regional intensive care network to improve quality of care and establish a platform for clinical trials in resource-limited settings in Asia ,NHMRC| the role of host MHC in HIV-1 sequence evolution, viral load and response to antiretroviral therapy ,EC| PREPARE ,NHMRC| Optimisation by Platform Trial Involving Multiple Interventions with Simultaneous Evaluation in Community Acquired Pneumonia (OPTIMISE-CAP) ,CIHRHesham Abdelhady; Marwa Abdelrazik; Zakee Abdi; David Abdo; Amina Abdulle; Lynn Abel; Shrefee Abouzeenni; Gail Abrahamson; Yousuf Abusamra; Lisa Adams; Olumide Adebambo; Debo Ademokun; Neill Adhikari; Dominic Affron; Anu Aggarwal; Ronan Agno; Humayun Ahmad; Norfaizan Ahmad; Sophia Ahmed; Kate Ainscough; James Ainsworth; Giulia Airoldi; Lindianne Aitken; Francis Ajeneye; Naim Akhtar; Olajide Akinwumiju; Manaf Al-Bayati; Martin Albert; Meera Alderman; Ana Alegria; Brian Alexander; Peter DG Alexander; Jordan Alfonso; Hoodo Ali; Sabira Ali; Allameddine Allameddine; Sheila Allan; Isabelle Allard; Barbara Allen; Beverley Allen; Jess Allen; Laura Allen; Louise Allen; Suzanne Allibone; Richard Ambrosino; Kenneth Amenyah; Mariam Ammoun; Rekha Anand; Sai Priya Anand; Kristen Andersen; Corinne Anderson; Kevin Anderson; Thomas Anderson; Mark Andreae; Susan Andrews; Gregory Andrikopoulos; Aisha Anjum; Matthew Anstey; Micheline Antar; David Antcliffe; Alpha Anthony; Pierre Antoine; Vikram Anumakonda; George Apostolides; Latha Aravindan; Gill Arbane; Emily Arbon; Simon Archer; Noah Aref; Ana-Marie Arias; Chantal Armali; Joel Armer-Ducker; Michelle Armstrong; Sylvia Armstrong-Fisher; John Arnold; Sarah Arnott; Andrea Arroyo; Valérie Arsenault; Diptesh Aryal; Adeeba Asghar; Glen Ashby; Deborah Asher; Ben Ashford; Suhail Ashgar; Murtaza Asif Ali; Angelique Aspinwall; Abigail Asquith; Tanya Atallah; Richard Athay-Hunt; Udara Attanayaka; Rita Atugonza; Michelle Aube; Marie-Christine Auclair; Karen Austin; Pauline Austin; Sidra Awan; Gina Bacon; Harleen Badhesha; Kavitha Bagavathy; Dawn Baglole; Clariza Bagnas; Catherine Bagot; Sean Bagshaw; Nadia Baig; Stephen Bailey; Kenneth Baillie; William Bain; Sanchia Baines; Aimi Baird; Charles Baker; Evelyn Baker; Penny Bakhtiari; Dhanalakshmi Bakthavatsalam; Morteza Balaie; Gagan Bali; Sonya Balkee; Amy Ballinger; Amy Bamford; Peter Bamford; Millie Banerjee; Lauren Banks; Jonathan Bannard-Smith; Nancy Banning; Bharat Bansal; Robert Banthorpe; Ian Barbash; Alex Barber; Russell Barber; Miriam Barbosa; Mercedes Barillas; Ryan Bariola; Gareth Barker; Nicky Barnes; Matthew Barnett; Nathaly Barnett; Rebecca Baron; Robert Bart; Jazz Bartholomew; Shauna Bartley; David Barton; Jan Barwell; Archana Bashyal; Kim Basile; Frances Bass; Christopher Bassford; Pavinder Bassi; Betsy Bassis; Ian Bateman; Michelle Bates; Samantha Bates; Donna Batty; Kris Bauchmuller; Peter Baughan; Lydia Baxter; Charlotte Baylem; Lee Bayliss; Madeleine Bayne; Eileen Bays; Renée Bazin; Gregory Beard; Kirk Beard; Richard Beasley; Lynette Beaudin; Julie Beaudoin; Guillaume Beaudoin-Bussières; Seonaid Beddows; Caroline Bedford; Deborah Beer; Salma Begum; Jasmine Beharry; Xiao Bei Zhao; Nathalie Belec; Gillian Bell; Glenda Bell; Joshua Bell; David Bellemare; Fatna Benettaib; Ann Beninato; Mehdi Benlarbi; Alexander Bennett; Christopher Bennett; Carrie Bennett-Mills; Andrea Benoit; Jane Benstead; Dionne Bentley; Lauren Berg; Colin Bergin; Claudia Berscheid; Janis Best-Lane; Emily Bevan; Jeremy Bewley; Ashley Beyerl; Sanjay Bhagani; Khushpreet Bhandal; Simon Biddie; Jennifer Biemans,; Kelly Bignell; Shilesh Bihari; Maude Bilodeau; Carron Bilton; Alexandra Binnie; Mark Brown; Paul Dark; Eamon Duffy; Ahilanandan Dushianthan; Neda Farahi; Niall Ferguson; Amaury Gaussen; Keith Gomez; Daniel Harvey; Stephanie B. Hatch; Anil Hormis; Devachandran Jayakumar; Shaman Jhanji; David Leaf; Gabriella Lindergard; Srinivas Murthy; Hayleah Pickford; Petra Polgarova; Jeffrey Presneill; Jérémie Prévost; Kathryn Puxty; Kathryn Rowan; Charlotte Summers; Katie Sweet; Andrew Ustianowski; Tonny Veenith; Maxime Veillette; Bala Venkatesh; Alicia Waite; Ingeborg D Welters; Joanna Willis; Paul Young; Lise J. Estcourt; Donald M. Arnold; Abigail Beane; James Daly; Lennie Derde; Cameron Green; Thomas E. Hills; Veronica C. Hoad; Nao Ichihara; Edward Litton; Daniel F. McAuley; Anna McGlothlin; Shay McGuinness; Paul R. Mouncey; Alistair Nichol; Luis F. Reyes; Jon A. Silversides; Anne M. Turner; Frank van de Veerdonk; David J. Roberts;IMPORTANCE: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive. OBJECTIVE: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021. INTERVENTIONS: The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916). MAIN OUTCOMES AND MEASURES: The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events. RESULTS: Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11 secondary outcomes. Serious adverse events were reported in 3.0% (32/1075) of participants in the convalescent plasma group and in 1.3% (12/905) of participants in the no convalescent plasma group. CONCLUSIONS AND RELEVANCE: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707. Contains fulltext : 245678.pdf (Publisher’s version ) (Closed access)
Radboud Repository arrow_drop_down The University of Manchester - Institutional RepositoryArticle . 2021Data sources: The University of Manchester - Institutional RepositorySpiral - Imperial College Digital RepositoryArticle . 2021Data sources: Spiral - Imperial College Digital RepositoryOxford University Research ArchiveOther literature type . 2021Data sources: Oxford University Research ArchiveHAL Descartes; Mémoires en Sciences de l'Information et de la CommunicationConference object . 2021JAMA; METIS Research Information SystemArticle . 2021 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1001/jama.2021.18178&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen bronze 159 citations 159 popularity Top 0.1% influence Top 10% impulse Top 0.1% Powered by BIP!visibility 23visibility views 23 Powered bymore_vert Radboud Repository arrow_drop_down The University of Manchester - Institutional RepositoryArticle . 2021Data sources: The University of Manchester - Institutional RepositorySpiral - Imperial College Digital RepositoryArticle . 2021Data sources: Spiral - Imperial College Digital RepositoryOxford University Research ArchiveOther literature type . 2021Data sources: Oxford University Research ArchiveHAL Descartes; Mémoires en Sciences de l'Information et de la CommunicationConference object . 2021JAMA; METIS Research Information SystemArticle . 2021 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1001/jama.2021.18178&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 FrancePublisher:Elsevier BV Funded by:EC | ECSTATICEC| ECSTATICBustin, Aurelien; Sridi, Soumaya; Gravinay, Pierre; Legghe, Benoit; Gosse, Philippe; Ouattara, Alexandre; Roze, Hadrien; Coste, Pierre; Gerbaud, Edouard; Desclaux, Arnaud; Boyer, Alexandre; Prevel, Renaud; Gruson, Didier; Bonnet, Fabrice; Issa, Nahema; Montaudon, Michel; Laurent, Francois; Stuber, Matthias; Camou, Fabrice; Cochet, Hubert;International audience; PURPOSE: High-resolution free-breathing late gadolinium enhancement (HR-LGE) was shown valuable for the diagnosis of acute coronary syndromes with non-obstructed coronary arteries. The method may be useful to detect COVID-related myocardial injuries but is hampered by prolonged acquisition times. We aimed to introduce an accelerated HR-LGE technique for the diagnosis of COVID-related myocardial injuries. METHOD: An undersampled navigator-gated HR-LGE (acquired resolution of 1.25 mm(3)) sequence combined with advanced patch-based low-rank reconstruction was developed and validated in a phantom and in 23 patients with structural heart disease (test cohort; 15 men; 55 ± 16 years). Twenty patients with laboratory-confirmed COVID-19 infection associated with troponin rise (COVID cohort; 15 men; 46 ± 24 years) prospectively underwent cardiovascular magnetic resonance (CMR) with the proposed sequence in our center. Image sharpness, quality, signal intensity differences and diagnostic value of free-breathing HR-LGE were compared against conventional breath-held low-resolution LGE (LR-LGE, voxel size 1.8x1.4x6mm). RESULTS: Structures sharpness in the phantom showed no differences with the fully sampled image up to an undersampling factor of x3.8 (P > 0.5). In patients (N = 43), this acceleration allowed for acquisition times of 7min21s ± 1min12s at 1.25 mm(3) resolution. Compared with LR-LGE, HR-LGE showed higher image quality (P = 0.03) and comparable signal intensity differences (P > 0.5). In patients with structural heart disease, all LGE-positive segments on LR-LGE were also detected on HR-LGE (80/391) with 21 additional enhanced segments visible only on HR-LGE (101/391, P < 0.001). In 4 patients with COVID-19 history, HR-LGE was definitely positive while LR-LGE was either definitely negative (1 microinfarction and 1 myocarditis) or inconclusive (2 myocarditis). CONCLUSIONS: Undersampled free-breathing isotropic HR-LGE can detect additional areas of late enhancement as compared to conventional breath-held LR-LGE. In patients with history of COVID-19 infection associated with troponin rise, the method allows for detailed characterization of myocardial injuries in acceptable scan times and without the need for repeated breath holds.
European Journal of ... arrow_drop_down European Journal of RadiologyArticle . 2021Full-Text: http://europepmc.org/articles/PMC8450147Data sources: PubMed CentralEuropean Journal of RadiologyArticle . 2021 . Peer-reviewedLicense: CC BY NC NDData sources: CrossrefMémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BY NC NDFull-Text: https://hal.science/hal-03440211/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.ejrad.2021.109960&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 5 citations 5 popularity Top 10% influence Average impulse Average Powered by BIP!visibility 20visibility views 20 download downloads 52 Powered bymore_vert European Journal of ... arrow_drop_down European Journal of RadiologyArticle . 2021Full-Text: http://europepmc.org/articles/PMC8450147Data sources: PubMed CentralEuropean Journal of RadiologyArticle . 2021 . Peer-reviewedLicense: CC BY NC NDData sources: CrossrefMémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BY NC NDFull-Text: https://hal.science/hal-03440211/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.ejrad.2021.109960&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu
Loading
description Publicationkeyboard_double_arrow_right Article 2021 Belgium, FrancePublisher:Springer Science and Business Media LLC Funded by:EC | MOOD, EC | RECoVEREC| MOOD ,EC| RECoVERDelphine Planas; Nell Saunders; Piet Maes; Florence Guivel-Benhassine; Cyril Planchais; Julian Buchrieser; William-Henry Bolland; Françoise Porrot; Isabelle Staropoli; Frederic Lemoine; Hélène Péré; David Veyer; Julien Puech; Julien Rodary; Guy Baele; Simon Dellicour; Joren Raymenants; Sarah Gorissen; Caspar Geenen; Bert Vanmechelen; Tony Wawina-Bokalanga; Joan Martí-Carreras; Lize Cuypers; Aymeric Sève; Laurent Hocqueloux; Thierry Prazuck; Félix A. Rey; Etienne Simon-Loriere; Timothée Bruel; Hugo Mouquet; Emmanuel André; Olivier Schwartz;The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa1-3. It has since spread to many countries and is expected to rapidly become dominant worldwide. The lineage is characterized by the presence of around 32 mutations in spike-located mostly in the N-terminal domain and the receptor-binding domain-that may enhance viral fitness and enable antibody evasion. Here we isolated an infectious Omicron virus in Belgium from a traveller returning from Egypt. We examined its sensitivity to nine monoclonal antibodies that have been clinically approved or are in development4, and to antibodies present in 115 serum samples from COVID-19 vaccine recipients or individuals who have recovered from COVID-19. Omicron was completely or partially resistant to neutralization by all monoclonal antibodies tested. Sera from recipients of the Pfizer or AstraZeneca vaccine, sampled five months after complete vaccination, barely inhibited Omicron. Sera from COVID-19-convalescent patients collected 6 or 12 months after symptoms displayed low or no neutralizing activity against Omicron. Administration of a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titres 6-fold to 23-fold lower against Omicron compared with those against Delta. Thus, Omicron escapes most therapeutic monoclonal antibodies and, to a large extent, vaccine-elicited antibodies. However, Omicron is neutralized by antibodies generated by a booster vaccine dose. ispartof: NATURE vol:602 issue:7898 pages:671-+ ispartof: location:England status: published
add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/d41586-021-03827-2&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 1K citations 1,056 popularity Top 0.01% influence Top 0.1% impulse Top 0.01% Powered by BIP!more_vert add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/d41586-021-03827-2&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Preprint 2021 FrancePublisher:Cold Spring Harbor Laboratory Funded by:NIH | Mechanisms of viral prote..., ANR | NICOFIVE, EC | SCORE +2 projectsNIH| Mechanisms of viral proteases in coronavirus replication and pathogenesis ,ANR| NICOFIVE ,EC| SCORE ,ANR| microFLU-REASSORT ,NIH| Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2K.Y. Chen; T. Krischuns; L. Ortega Varga; E. Harigua-Souiai; S. Paisant; A. Zettor; J. Chiaravalli; A. Delpal; D. Courtney; A. O'Brien; S.C. Baker; E. Decroly; C. Isel; F. Agou; Y. Jacob; A. Blondel; N. Naffakh;pmc: PMC8722588 , PMC8906008
AbstractEffective drugs against SARS-CoV-2 are urgently needed to treat severe cases of infection and for prophylactic use. The main viral protease (nsp5 or 3CLpro) represents an attractive and possibly broad-spectrum target for drug development as it is essential to the virus life cycle and highly conserved among betacoronaviruses. Sensitive and efficient high-throughput screening methods are key for drug discovery. Here we report the development of a gain-of-signal, highly sensitive cell-based luciferase assay to monitor SARS-CoV-2 nsp5 activity and show that it is suitable for high-throughput screening of compounds in a 384-well format. A benefit of miniaturisation and automation is that screening can be performed in parallel on a wild-type and a catalytically inactive nsp5, which improves the selectivity of the assay. We performed molecular docking-based screening on a set of 14,468 compounds from an in-house chemical database, selected 359 candidate nsp5 inhibitors and tested them experimentally. We identified four molecules, including the broad-spectrum antiviral merimepodib/VX-497, which show anti-nsp5 activity and inhibit SARS-CoV-2 replication in A549-ACE2 cells with IC50 values in the 4-21 µM range. The here described assay will allow the screening of large-scale compound libraries for SARS-CoV-2 nsp5 inhibitors. Moreover, we provide evidence that this assay can be adapted to other coronaviruses and viruses which rely on a viral protease.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8722588Data sources: PubMed CentralHAL Descartes; HAL-Pasteur; Mémoires en Sciences de l'Information et de la Communication; HAL AMUArticle . 2022License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.18.473303&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen hybrid 9 citations 9 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8722588Data sources: PubMed CentralHAL Descartes; HAL-Pasteur; Mémoires en Sciences de l'Information et de la Communication; HAL AMUArticle . 2022License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.18.473303&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Preprint 2021 FrancePublisher:Cold Spring Harbor Laboratory Funded by:EC | STRUGGLE, EC | QuanTIIEC| STRUGGLE ,EC| QuanTIIAuthors: Ruiz Ortega, María; Spisak, Natanael; Mora, Thierry; Walczak, Aleksandra M.;Ruiz Ortega, María; Spisak, Natanael; Mora, Thierry; Walczak, Aleksandra M.;Adaptive immunity’s success relies on the extraordinary diversity of protein receptors on B and T cell membranes. Despite this diversity, the existence of public receptors shared by many individuals gives hope for developing population wide vaccines and therapeutics. Yet many of these public receptors are shared by chance. We present a statistical approach, defined in terms of a probabilistic V(D)J recombination model enhanced by a selection factor, that describes repertoire diversity and predicts with high accuracy the spectrum of repertoire overlap in healthy individuals. The model underestimates sharing between repertoires of individuals infected with SARS-CoV-2, suggesting strong antigen-driven convergent selection. We exploit this discrepancy to identify COVID-associated receptors, which we validate against datasets of receptors with known viral specificity. We study their properties in terms of sequence features and network organization, and use them to design an accurate diagnosis tool for predicting SARS-CoV-2 status from repertoire data.
PLoS Genetics arrow_drop_down https://doi.org/10.1101/2021.1...Other literature type . Preprint . 2021 . 2022Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2022add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.17.473105&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesgold 10 citations 10 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert PLoS Genetics arrow_drop_down https://doi.org/10.1101/2021.1...Other literature type . Preprint . 2021 . 2022Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2022add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1101/2021.12.17.473105&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Preprint , Other literature type 2021Embargo end date: 15 Dec 2021 United Kingdom, FrancePublisher:Apollo - University of Cambridge Repository Funded by:EC | VEO, ANR | INCEPTION, EC | RECoVEREC| VEO ,ANR| INCEPTION ,EC| RECoVERTran Kiem, Cécile; Bosetti, Paolo; Paireau, Juliette; Crépey, Pascal; Salje, Henrik; Lefrancq, Noémie; Fontanet, Arnaud; Benamouzig, Daniel; Boëlle, Pierre-Yves; Desenclos, Jean-Claude; Opatowski, Lulla; Cauchemez, Simon;The shielding of older individuals has been proposed to limit COVID-19 hospitalizations while relaxing general social distancing in the absence of vaccines. Evaluating such approaches requires a deep understanding of transmission dynamics across ages. Here, we use detailed age-specific case and hospitalization data to model the rebound in the French epidemic in summer 2020, characterize age-specific transmission dynamics and critically evaluate different age-targeted intervention measures in the absence of vaccines. We find that while the rebound started in young adults, it reached individuals aged ���80 y.o. after 4 weeks, despite substantial contact reductions, indicating substantial transmission flows across ages. We derive the contribution of each age group to transmission. While shielding older individuals reduces mortality, it is insufficient to allow major relaxations of social distancing. When the epidemic remains manageable (R close to 1), targeting those most contributing to transmission is better than shielding at-risk individuals. Pandemic control requires an effort from all age groups. Funder: We acknowledge financial support from the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Sant�� Publique France, the INCEPTION project (PIA/ANR-16-COV-0005), the European Union���s Horizon 2020 research and innovation program under grant 101003589 (RECOVER) and 874735 (VEO), AXA and Groupama. Funder: AXA Research Fund (Le Fonds AXA pour la Recherche); doi: https://doi.org/10.13039/501100001961
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021 . Peer-reviewedFull-Text: http://europepmc.org/articles/PMC8617041Data sources: PubMed CentralHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461/documentHAL Descartes; HAL-Rennes 1; HAL-Pasteur; Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2021License: CC BY NC NDHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la Communication; Hal-DiderotPreprint . 2021License: CC BY NC NDHAL DescartesArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461v3/documentData sources: HAL Descartesadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.17863/cam.78875&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu4 citations 4 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021 . Peer-reviewedFull-Text: http://europepmc.org/articles/PMC8617041Data sources: PubMed CentralHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461/documentHAL Descartes; HAL-Rennes 1; HAL-Pasteur; Mémoires en Sciences de l'Information et de la CommunicationPreprint . 2021License: CC BY NC NDHAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la Communication; Hal-DiderotPreprint . 2021License: CC BY NC NDHAL DescartesArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03468461v3/documentData sources: HAL Descartesadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.17863/cam.78875&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Conference object , Preprint , Article 2021 FrancePublisher:IEEE Funded by:EC | Scale-FreeBackEC| Scale-FreeBackAuthors: Niazi, Muhammad Umar B.; Kibangou, Alain; Canudas-de-Wit, Carlos; Nikitin, Denis; +2 AuthorsNiazi, Muhammad Umar B.; Kibangou, Alain; Canudas-de-Wit, Carlos; Nikitin, Denis; Tumash, Liudmila; Bliman, Pierre-Alexandre;Testing is a crucial control mechanism for an epidemic outbreak because it enables the health authority to detect and isolate the infected cases, thereby limiting the disease transmission to susceptible people, when no effective treatment or vaccine is available. In this paper, an epidemic model that incorporates the testing rate as a control input is presented. The proposed model distinguishes between the undetected infected and the detected infected cases with the latter assumed to be isolated from the disease spreading process in the population. Two testing policies, effective during the onset of an epidemic when no treatment or vaccine is available, are devised: (i) best-effort strategy for testing (BEST) and (ii) constant optimal strategy for testing (COST). The BEST is a suppression policy that provides a lower bound on the testing rate to stop the growth of the epidemic. The COST is a mitigation policy that minimizes the peak of the epidemic by providing a constant, optimal allocation of tests in a certain time interval when the total stockpile of tests is limited. Both testing policies are evaluated by their impact on the number of active intensive care unit (ICU) cases and the cumulative number of deaths due to COVID-19 in France. arXiv admin note: substantial text overlap with arXiv:2010.15438
https://hal.archives... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/cdc45484.2021.9683300&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen 0 citations 0 popularity Average influence Average impulse Average Powered by BIP!more_vert https://hal.archives... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/cdc45484.2021.9683300&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 France, ItalyPublisher:Springer Science and Business Media LLC Funded by:ANR | EVALCOVID-19, EC | MOOD, EC | RECoVERANR| EVALCOVID-19 ,EC| MOOD ,EC| RECoVERLaura Di Domenico; Chiara E. Sabbatini; Pierre-Yves Boëlle; Chiara Poletto; Pascal Crépey; Juliette Paireau; Simon Cauchemez; François Beck; Harold Noel; Daniel Lévy-Bruhl; Vittoria Colizza;After one year of stop-and-go COVID-19 mitigation, in the spring of 2021 European countries still experienced sustained viral circulation due to the Alpha variant. As the prospect of entering a new pandemic phase through vaccination was drawing closer, a key challenge remained on how to balance the efficacy of long-lasting interventions and their impact on the quality of life.Focusing on the third wave in France during spring 2021, we simulate intervention scenarios of varying intensity and duration, with potential waning of adherence over time, based on past mobility data and modeling estimates. We identify optimal strategies by balancing efficacy of interventions with a data-driven "distress" index, integrating intensity and duration of social distancing.We show that moderate interventions would require a much longer time to achieve the same result as high intensity lockdowns, with the additional risk of deteriorating control as adherence wanes. Shorter strict lockdowns are largely more effective than longer moderate lockdowns, for similar intermediate distress and infringement on individual freedom.Our study shows that favoring milder interventions over more stringent short approaches on the basis of perceived acceptability could be detrimental in the long term, especially with waning adherence.In the spring of 2021, social distancing measures were strengthened in France to control the third wave of COVID-19 cases. While such measures are needed to slow the spread of the virus, they have a significant impact on the population’s quality of life. Here, we use mathematical modelling based on hospital admission data and behavioural and health data (including data on mobility, indicators of social distancing, risk perception, and mental health) to evaluate optimal COVID-19 control strategies. We look at the effects of interventions, their sustainability and the population’s adherence to them over time. We find that shorter, more stringent measures are likely to have similar effects on viral circulation and healthcare burden to long-lasting, less stringent but less sustainable interventions. Our findings have implications for the design and implementation of public health measures to control future COVID-19 waves.
Archivio istituziona... arrow_drop_down HAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03690599/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s43856-021-00057-5&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesgold 16 citations 16 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert Archivio istituziona... arrow_drop_down HAL Descartes; HAL-Rennes 1; HAL-Pasteur; HAL-Inserm; Mémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BYFull-Text: https://hal.science/hal-03690599/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s43856-021-00057-5&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 France, France, NetherlandsPublisher:Elsevier BV Funded by:ANR | FIGHT-HF, EC | HOMAGEANR| FIGHT-HF ,EC| HOMAGEAuthors: Ferreira, João Pedro; Girerd, Nicolas; Rocca, Hans-Peter Brunner-La; Pellicori, Pierpaolo; +3 AuthorsFerreira, João Pedro; Girerd, Nicolas; Rocca, Hans-Peter Brunner-La; Pellicori, Pierpaolo; Cleland, John; Rossignol, Patrick; Zannad, Faiez;International audience
Archives of Cardiova... arrow_drop_down Archives of Cardiovascular DiseasesArticle . 2021Full-Text: http://europepmc.org/articles/PMC8576594Data sources: PubMed CentralArchives of Cardiovascular Diseases; NARCISArticle . 2021add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.acvd.2021.10.003&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 3 citations 3 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert Archives of Cardiova... arrow_drop_down Archives of Cardiovascular DiseasesArticle . 2021Full-Text: http://europepmc.org/articles/PMC8576594Data sources: PubMed CentralArchives of Cardiovascular Diseases; NARCISArticle . 2021add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.acvd.2021.10.003&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 FrancePublisher:Wiley Publicly fundedFunded by:IRC, ANR | PSL, EC | PhotoMedMetIRC ,ANR| PSL ,EC| PhotoMedMetGil‐Moles, Maria; Türck, Sebastian; Basu, Uttara; Pettenuzzo, Andrea; Bhattacharya, Saurav; Rajan, Ananthu; Ma, Xiang; Büssing, Rolf; Wölker, Jessica; Burmeister, Hilke; Hoffmeister, Henrik; Schneeberg, Pia; Prause, Andre; Lippmann, Petra; Kusi‐Nimarko, Josephine; Hassell‐Hart, Storm; McGown, Andrew; Guest, Daniel; Lin, Yan; Notaro, Anna; Vinck, Robin; Karges, Johannes; Cariou, Kevin; Peng, Kun; Qin, Xue; Wang, Xing; Skiba, Joanna; Szczupak, Łukasz; Kowalski, Konrad; Schatzschneider, Ulrich; Hemmert, Catherine; Gornitzka, Heinz; Milaeva, Elena R.; Nazarov, Alexey A.; Gasser, Gilles; Spencer, John; Ronconi, Luca; Kortz, Ulrich; Cinatl, Jindrich; Bojkova, Denisa; Ott, Ingo;Abstract The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are commonly underrepresented in compound libraries that are used for screening in drug discovery campaigns, however, there is growing evidence for their role in medicinal chemistry. Based on previous results, we have selected more than 100 structurally diverse metal complexes for profiling as inhibitors of two relevant SARS‐CoV‐2 replication mechanisms, namely the interaction of the spike (S) protein with the ACE2 receptor and the papain‐like protease PLpro. In addition to many well‐established types of mononuclear experimental metallodrugs, the pool of compounds tested was extended to approved metal‐based therapeutics such as silver sulfadiazine and thiomersal, as well as polyoxometalates (POMs). Among the mononuclear metal complexes, only a small number of active inhibitors of the S/ACE2 interaction was identified, with titanocene dichloride as the only strong inhibitor. However, among the gold and silver containing complexes many turned out to be very potent inhibitors of PLpro activity. Highly promising activity against both targets was noted for many POMs. Selected complexes were evaluated in antiviral SARS‐CoV‐2 assays confirming activity for gold complexes with N‐heterocyclic carbene (NHC) or dithiocarbamato ligands, a silver NHC complex, titanocene dichloride as well as a POM compound. These studies might provide starting points for the design of metal‐based SARS‐CoV‐2 antiviral agents. Despite their increasing relevance in medicinal chemistry, metal complexes are still underrepresented in compound screening libraries for drug discovery. In this work more than 100 metal complexes were evaluated as inhibitors of two targets in the SARS‐CoV‐2 life cycle, the interaction of the spike protein with the ACE2 receptor and the protease PLpro. The most active inhibitors were studied for antiviral effects in SARS‐CoV‐2 infected cells and led to the discovery of active compounds that will provide starting points for future drug design.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8653295Data sources: PubMed CentralMémoires en Sciences de l'Information et de la CommunicationArticle . 2021Full-Text: https://hal.science/hal-03722017/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1002/chem.202103258&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen hybrid 33 citations 33 popularity Top 10% influence Top 10% impulse Top 10% Powered by BIP!visibility 44visibility views 44 download downloads 10 Powered bymore_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2021Full-Text: http://europepmc.org/articles/PMC8653295Data sources: PubMed CentralMémoires en Sciences de l'Information et de la CommunicationArticle . 2021Full-Text: https://hal.science/hal-03722017/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1002/chem.202103258&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Other literature type , Conference object 2021 United Kingdom, Belgium, United Kingdom, United Kingdom, France, United Kingdom, United Kingdom, United Kingdom, United Kingdom, Netherlands, FrancePublisher:American Medical Association (AMA) Publicly fundedFunded by:WT | Implementing an innovativ..., NHMRC | the role of host MHC in H..., EC | PREPARE +2 projectsWT| Implementing an innovative electronic registry in a new regional intensive care network to improve quality of care and establish a platform for clinical trials in resource-limited settings in Asia ,NHMRC| the role of host MHC in HIV-1 sequence evolution, viral load and response to antiretroviral therapy ,EC| PREPARE ,NHMRC| Optimisation by Platform Trial Involving Multiple Interventions with Simultaneous Evaluation in Community Acquired Pneumonia (OPTIMISE-CAP) ,CIHRHesham Abdelhady; Marwa Abdelrazik; Zakee Abdi; David Abdo; Amina Abdulle; Lynn Abel; Shrefee Abouzeenni; Gail Abrahamson; Yousuf Abusamra; Lisa Adams; Olumide Adebambo; Debo Ademokun; Neill Adhikari; Dominic Affron; Anu Aggarwal; Ronan Agno; Humayun Ahmad; Norfaizan Ahmad; Sophia Ahmed; Kate Ainscough; James Ainsworth; Giulia Airoldi; Lindianne Aitken; Francis Ajeneye; Naim Akhtar; Olajide Akinwumiju; Manaf Al-Bayati; Martin Albert; Meera Alderman; Ana Alegria; Brian Alexander; Peter DG Alexander; Jordan Alfonso; Hoodo Ali; Sabira Ali; Allameddine Allameddine; Sheila Allan; Isabelle Allard; Barbara Allen; Beverley Allen; Jess Allen; Laura Allen; Louise Allen; Suzanne Allibone; Richard Ambrosino; Kenneth Amenyah; Mariam Ammoun; Rekha Anand; Sai Priya Anand; Kristen Andersen; Corinne Anderson; Kevin Anderson; Thomas Anderson; Mark Andreae; Susan Andrews; Gregory Andrikopoulos; Aisha Anjum; Matthew Anstey; Micheline Antar; David Antcliffe; Alpha Anthony; Pierre Antoine; Vikram Anumakonda; George Apostolides; Latha Aravindan; Gill Arbane; Emily Arbon; Simon Archer; Noah Aref; Ana-Marie Arias; Chantal Armali; Joel Armer-Ducker; Michelle Armstrong; Sylvia Armstrong-Fisher; John Arnold; Sarah Arnott; Andrea Arroyo; Valérie Arsenault; Diptesh Aryal; Adeeba Asghar; Glen Ashby; Deborah Asher; Ben Ashford; Suhail Ashgar; Murtaza Asif Ali; Angelique Aspinwall; Abigail Asquith; Tanya Atallah; Richard Athay-Hunt; Udara Attanayaka; Rita Atugonza; Michelle Aube; Marie-Christine Auclair; Karen Austin; Pauline Austin; Sidra Awan; Gina Bacon; Harleen Badhesha; Kavitha Bagavathy; Dawn Baglole; Clariza Bagnas; Catherine Bagot; Sean Bagshaw; Nadia Baig; Stephen Bailey; Kenneth Baillie; William Bain; Sanchia Baines; Aimi Baird; Charles Baker; Evelyn Baker; Penny Bakhtiari; Dhanalakshmi Bakthavatsalam; Morteza Balaie; Gagan Bali; Sonya Balkee; Amy Ballinger; Amy Bamford; Peter Bamford; Millie Banerjee; Lauren Banks; Jonathan Bannard-Smith; Nancy Banning; Bharat Bansal; Robert Banthorpe; Ian Barbash; Alex Barber; Russell Barber; Miriam Barbosa; Mercedes Barillas; Ryan Bariola; Gareth Barker; Nicky Barnes; Matthew Barnett; Nathaly Barnett; Rebecca Baron; Robert Bart; Jazz Bartholomew; Shauna Bartley; David Barton; Jan Barwell; Archana Bashyal; Kim Basile; Frances Bass; Christopher Bassford; Pavinder Bassi; Betsy Bassis; Ian Bateman; Michelle Bates; Samantha Bates; Donna Batty; Kris Bauchmuller; Peter Baughan; Lydia Baxter; Charlotte Baylem; Lee Bayliss; Madeleine Bayne; Eileen Bays; Renée Bazin; Gregory Beard; Kirk Beard; Richard Beasley; Lynette Beaudin; Julie Beaudoin; Guillaume Beaudoin-Bussières; Seonaid Beddows; Caroline Bedford; Deborah Beer; Salma Begum; Jasmine Beharry; Xiao Bei Zhao; Nathalie Belec; Gillian Bell; Glenda Bell; Joshua Bell; David Bellemare; Fatna Benettaib; Ann Beninato; Mehdi Benlarbi; Alexander Bennett; Christopher Bennett; Carrie Bennett-Mills; Andrea Benoit; Jane Benstead; Dionne Bentley; Lauren Berg; Colin Bergin; Claudia Berscheid; Janis Best-Lane; Emily Bevan; Jeremy Bewley; Ashley Beyerl; Sanjay Bhagani; Khushpreet Bhandal; Simon Biddie; Jennifer Biemans,; Kelly Bignell; Shilesh Bihari; Maude Bilodeau; Carron Bilton; Alexandra Binnie; Mark Brown; Paul Dark; Eamon Duffy; Ahilanandan Dushianthan; Neda Farahi; Niall Ferguson; Amaury Gaussen; Keith Gomez; Daniel Harvey; Stephanie B. Hatch; Anil Hormis; Devachandran Jayakumar; Shaman Jhanji; David Leaf; Gabriella Lindergard; Srinivas Murthy; Hayleah Pickford; Petra Polgarova; Jeffrey Presneill; Jérémie Prévost; Kathryn Puxty; Kathryn Rowan; Charlotte Summers; Katie Sweet; Andrew Ustianowski; Tonny Veenith; Maxime Veillette; Bala Venkatesh; Alicia Waite; Ingeborg D Welters; Joanna Willis; Paul Young; Lise J. Estcourt; Donald M. Arnold; Abigail Beane; James Daly; Lennie Derde; Cameron Green; Thomas E. Hills; Veronica C. Hoad; Nao Ichihara; Edward Litton; Daniel F. McAuley; Anna McGlothlin; Shay McGuinness; Paul R. Mouncey; Alistair Nichol; Luis F. Reyes; Jon A. Silversides; Anne M. Turner; Frank van de Veerdonk; David J. Roberts;IMPORTANCE: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive. OBJECTIVE: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021. INTERVENTIONS: The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916). MAIN OUTCOMES AND MEASURES: The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events. RESULTS: Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11 secondary outcomes. Serious adverse events were reported in 3.0% (32/1075) of participants in the convalescent plasma group and in 1.3% (12/905) of participants in the no convalescent plasma group. CONCLUSIONS AND RELEVANCE: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707. Contains fulltext : 245678.pdf (Publisher’s version ) (Closed access)
Radboud Repository arrow_drop_down The University of Manchester - Institutional RepositoryArticle . 2021Data sources: The University of Manchester - Institutional RepositorySpiral - Imperial College Digital RepositoryArticle . 2021Data sources: Spiral - Imperial College Digital RepositoryOxford University Research ArchiveOther literature type . 2021Data sources: Oxford University Research ArchiveHAL Descartes; Mémoires en Sciences de l'Information et de la CommunicationConference object . 2021JAMA; METIS Research Information SystemArticle . 2021 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1001/jama.2021.18178&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen bronze 159 citations 159 popularity Top 0.1% influence Top 10% impulse Top 0.1% Powered by BIP!visibility 23visibility views 23 Powered bymore_vert Radboud Repository arrow_drop_down The University of Manchester - Institutional RepositoryArticle . 2021Data sources: The University of Manchester - Institutional RepositorySpiral - Imperial College Digital RepositoryArticle . 2021Data sources: Spiral - Imperial College Digital RepositoryOxford University Research ArchiveOther literature type . 2021Data sources: Oxford University Research ArchiveHAL Descartes; Mémoires en Sciences de l'Information et de la CommunicationConference object . 2021JAMA; METIS Research Information SystemArticle . 2021 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1001/jama.2021.18178&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2021 FrancePublisher:Elsevier BV Funded by:EC | ECSTATICEC| ECSTATICBustin, Aurelien; Sridi, Soumaya; Gravinay, Pierre; Legghe, Benoit; Gosse, Philippe; Ouattara, Alexandre; Roze, Hadrien; Coste, Pierre; Gerbaud, Edouard; Desclaux, Arnaud; Boyer, Alexandre; Prevel, Renaud; Gruson, Didier; Bonnet, Fabrice; Issa, Nahema; Montaudon, Michel; Laurent, Francois; Stuber, Matthias; Camou, Fabrice; Cochet, Hubert;International audience; PURPOSE: High-resolution free-breathing late gadolinium enhancement (HR-LGE) was shown valuable for the diagnosis of acute coronary syndromes with non-obstructed coronary arteries. The method may be useful to detect COVID-related myocardial injuries but is hampered by prolonged acquisition times. We aimed to introduce an accelerated HR-LGE technique for the diagnosis of COVID-related myocardial injuries. METHOD: An undersampled navigator-gated HR-LGE (acquired resolution of 1.25 mm(3)) sequence combined with advanced patch-based low-rank reconstruction was developed and validated in a phantom and in 23 patients with structural heart disease (test cohort; 15 men; 55 ± 16 years). Twenty patients with laboratory-confirmed COVID-19 infection associated with troponin rise (COVID cohort; 15 men; 46 ± 24 years) prospectively underwent cardiovascular magnetic resonance (CMR) with the proposed sequence in our center. Image sharpness, quality, signal intensity differences and diagnostic value of free-breathing HR-LGE were compared against conventional breath-held low-resolution LGE (LR-LGE, voxel size 1.8x1.4x6mm). RESULTS: Structures sharpness in the phantom showed no differences with the fully sampled image up to an undersampling factor of x3.8 (P > 0.5). In patients (N = 43), this acceleration allowed for acquisition times of 7min21s ± 1min12s at 1.25 mm(3) resolution. Compared with LR-LGE, HR-LGE showed higher image quality (P = 0.03) and comparable signal intensity differences (P > 0.5). In patients with structural heart disease, all LGE-positive segments on LR-LGE were also detected on HR-LGE (80/391) with 21 additional enhanced segments visible only on HR-LGE (101/391, P < 0.001). In 4 patients with COVID-19 history, HR-LGE was definitely positive while LR-LGE was either definitely negative (1 microinfarction and 1 myocarditis) or inconclusive (2 myocarditis). CONCLUSIONS: Undersampled free-breathing isotropic HR-LGE can detect additional areas of late enhancement as compared to conventional breath-held LR-LGE. In patients with history of COVID-19 infection associated with troponin rise, the method allows for detailed characterization of myocardial injuries in acceptable scan times and without the need for repeated breath holds.
European Journal of ... arrow_drop_down European Journal of RadiologyArticle . 2021Full-Text: http://europepmc.org/articles/PMC8450147Data sources: PubMed CentralEuropean Journal of RadiologyArticle . 2021 . Peer-reviewedLicense: CC BY NC NDData sources: CrossrefMémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BY NC NDFull-Text: https://hal.science/hal-03440211/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.ejrad.2021.109960&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 5 citations 5 popularity Top 10% influence Average impulse Average Powered by BIP!visibility 20visibility views 20 download downloads 52 Powered bymore_vert European Journal of ... arrow_drop_down European Journal of RadiologyArticle . 2021Full-Text: http://europepmc.org/articles/PMC8450147Data sources: PubMed CentralEuropean Journal of RadiologyArticle . 2021 . Peer-reviewedLicense: CC BY NC NDData sources: CrossrefMémoires en Sciences de l'Information et de la CommunicationArticle . 2021License: CC BY NC NDFull-Text: https://hal.science/hal-03440211/documentadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1016/j.ejrad.2021.109960&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu